Zacks: Brokerages Expect Lipocine Inc. (LPCN) Will Post Earnings of -$0.33 Per Share
Brokerages forecast that Lipocine Inc. (NASDAQ:LPCN) will announce ($0.33) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Lipocine’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.38). Lipocine reported earnings per share of ($0.32) in the same quarter last year, which would suggest a negative year over year growth rate of 3.1%. The company is scheduled to announce its next earnings results on Tuesday, August 8th.
According to Zacks, analysts expect that Lipocine will report full year earnings of ($1.16) per share for the current year, with EPS estimates ranging from ($1.87) to ($0.73). For the next year, analysts forecast that the company will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.53) to $0.25. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Lipocine.
Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.04.
LPCN has been the topic of several recent research reports. Roth Capital set a $38.00 price objective on Lipocine and gave the stock a “buy” rating in a research note on Tuesday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Lipocine in a research note on Wednesday, April 26th. Finally, Canaccord Genuity set a $10.00 price objective on Lipocine and gave the stock a “buy” rating in a research note on Monday, April 24th.
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/26/zacks-brokerages-expect-lipocine-inc-lpcn-will-post-earnings-of-0-33-per-share.html.
Lipocine (LPCN) traded down 6.89% on Monday, reaching $3.92. The company’s stock had a trading volume of 704,824 shares. The stock has a 50-day moving average of $3.77 and a 200-day moving average of $3.80. Lipocine has a one year low of $2.51 and a one year high of $7.78. The stock’s market cap is $75.50 million.
A number of hedge funds have recently modified their holdings of LPCN. Teachers Advisors LLC increased its stake in shares of Lipocine by 26.4% in the fourth quarter. Teachers Advisors LLC now owns 32,874 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 6,869 shares during the period. KCG Holdings Inc. increased its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 7,219 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after buying an additional 6,191 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Lipocine by 5.5% in the first quarter. Geode Capital Management LLC now owns 119,313 shares of the specialty pharmaceutical company’s stock valued at $465,000 after buying an additional 6,246 shares during the period. 38.59% of the stock is currently owned by institutional investors.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.